Previous 10 | Next 10 |
home / stock / adilw / adilw news
CHARLOTTESVILLE, VA / ACCESSWIRE / January 9, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received favorable opinions from the Finnish Medicines Agency ...
CHARLOTTESVILLE, VA / ACCESSWIRE / December 16, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received a Notice of Allowance for the issuance of a patent ...
Reports regulatory progress in Europe and imminent commencement of clinical trial CHARLOTTESVILLE, VA / ACCESSWIRE / December 13, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for a...
CHARLOTTESVILLE, VA / ACCESSWIRE / October 29, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL)(NASDAQ:ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has completed the final packaging of its lead in...
CHARLOTTESVILLE, VA / ACCESSWIRE / October 17, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received a Notice of Allowance for the issuance of a p...
CHARLOTTESVILLE, VA / ACCESSWIRE / October 1, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has submitted its Clinical Trial Application (CTA) to comme...
CHARLOTTESVILLE, VA / ACCESSWIRE / September 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its clinical activities. The Company reported that it is on...
CHARLOTTESVILLE, VA / ACCESSWIRE / September 11, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that its previously manufactured supply of clinical trial mater...
CHARLOTTESVILLE, VA / ACCESSWIRE / June 19, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ; ADILW ) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that its Chief Medical Officer, Bankole Johnson, M.D., D.Sc., M.B., ChB...
CHARLOTTESVILLE, VA / ACCESSWIRE / June 13, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the further strengthening of its intellectual property (IP) portfolio, as i...
News, Short Squeeze, Breakout and More Instantly...
Adial Pharmaceuticals Inc Warrant Company Name:
ADILW Stock Symbol:
NASDAQ Market:
Adial Pharmaceuticals Inc Warrant Website:
GLEN ALLEN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorder...
GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,...
Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studies and support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va., June 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: A...